When to start antiretroviral therapy during tuberculosis treatment?

Current Opinion in Infectious Diseases

Volumn 26, Issue 1, 2013, Pages 35-42

  Naidoo, Kogieleum ^a   Baxter, Cheryl ^a   Abdool Karim, Salim S ^a,b  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Department of Medicine   (United States)

Author keywords

antiretroviral therapy; HIV; immune reconstitution inflammatory syndrome; tuberculosis

Indexed keywords

DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE; RIFAMYCIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; DISEASE FREE SURVIVAL; DISEASE SEVERITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; MIXED INFECTION; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; TREATMENT DURATION; TUBERCULOSIS; TUBERCULOUS MENINGITIS; WORLD HEALTH ORGANIZATION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; COINFECTION; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUBERCULOSIS;

EID: 84871786601     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32835ba8f9     Document Type: Review

References (38)

1. UNAIDS. Together we will end AIDS. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2012. Available from http://www.unaids.org/en/resources/campaigns/togetherwewillendaids/[Accessed 2 August 2012].
2. WHO. Global tuberculosis control 2011. Geneva, Switzerland: World Health Organization; 2011. Available from http://www.who.int/tb/publications/global- report/2011/gtbr11-full.pdf [Accessed 12 March 2012].
3. Abdool Karim SS. Durban 2000 to Toronto 2006: the evolving challenges in implementing AIDS treatment in Africa. AIDS 2006; 20:N7-N9.
4. Churchyard GJ, Kleinschmidt I, Corbett EL, et al. Factors associated with an increased case-fatality rate in HIV-infected and noninfected South African gold miners with pulmonary tuberculosis. Int J Tuberc Lung Dis 2000; 4:705-712. (Pubitemid 30650029)
5. Mukadi YD, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15:143-152. (Pubitemid 32142288)
6. W.H.O. Global tuberculosis control 2011. Geneva, Switzerland: WHO; 2011. http://www.who.int/tb/publications/global-report/2011/gtbr11-full. pdf.
7. Schluger NW. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected participants. Clin Infect Dis 1999; 28:130-135. (Pubitemid 29246137)
8. Health Systems Trust. District Health Barometer 2006/2007. 2008. Accessible at http www.hst.org.za/publications/717 [Accessed January 2009].
9. Lawn SD, Myer L, Orrell C, et al. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148. (Pubitemid 41669003)
10. Murray J, Sonnenberg P, Shearer SC, Godfrey-Faussett P. Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients. Am J Respir Crit Care Med 1999; 159:733-740. (Pubitemid 29137767)
11. World Health Organisation. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva, Switzerland: World Health Organisation; 2003.
12. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001; 344:984-996. (Pubitemid 32240318)
13. Fishman JE, Saraf-Lavi E, Narita M, et al. Pulmonary tuberculosis in AIDS participants: transient chest radiographic worsening after initiation of antiretroviral therapy. Am J Roentgenol 2000; 174:43-49. (Pubitemid 30030205)
14. Chien JW, Johnson JL. Paradoxical reactions in HIV and pulmonary TB. Chest 1998; 114:933-936. (Pubitemid 28433762)
15. Girardi E, Palmieri F, Cingolani A, et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:326-331. (Pubitemid 32435996)
16. Abdool Karim SS, Abdool Karim Q, Friedland G, et al., on behalf of the START project. Implementing antiretroviral therapy in resource-constrained settings: opportunities and challenges in integrating HIV and tuberculosis care. AIDS 2004; 18:975-979. (Pubitemid 38591187)
17. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-152.
18. Manosuthi W, Chottanapand S, Thongyen S, et al. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43:42-46. (Pubitemid 44306486)
19. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIV-associated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190:1670-1676. (Pubitemid 39411018)
20. Dean GL, Edwards SG, Ives NJ, et al. Treatment of tuberculosis in HIVinfected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83. (Pubitemid 34062184)
21. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
22. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365:1492-1501.
23. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471-1481.
24. Degu WA, Lindquist L, Aderaye G, et al. Randomized clinical trial to determine efficacy and safety of ART 1 week after TB therapy in patients with CD4 counts 200 cells/mL [abstract]. Paper #144 CROI 2012, http://www. retroconference.org/2012b/Abstracts/44153.htm, 2012
25. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482-1491.
26. Franke MF, Robins JM, Mugabo J, et al. Effectiveness of early antiretroviral therapy initiation to improve survival among HIV-infected adults with tuberculosis: a retrospective cohort study. PLoS Med 2011; 8:e1001029.
27. Torok ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374-1383.
28. Bekker GL, Wood R. TB and HIV co-infection: when to start antiretroviral therapy. CME 2011; 29:420-426.
29. Naidoo K, Yende-Zuma N, Padayatchi N, et al. The immune reconstitution inflammatory syndrome after antiretroviral therapy initiation in patients with tuberculosis: findings from the SAPiT Trial. Ann Intern Med 2012; 157:312-324.
30. Klein R, Struble K. Sustiva labeling update/dosing adjustment with rifampin. http://www.natap.org/2012/newsUpdates/010612-06.htm. 2012.
31. Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012; 68:689-695.
32. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine-or efavirenz-based antiretroviral therapy in HIVassociated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011; 53:716-724.
33. Nijland HM, L'Homme RF, RongenGA, et al. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 2008; 22:931-935. (Pubitemid 351652243)
34. WHO. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. 2012. http://www.who.int/tb/ publications/2012/tb-hiv-policy-9789241503006/en/index.html [Accessed 29 August 2012].
35. Howard AA, Gasana M, Getahun H, et al. PEPFAR support for the scaling up of collaborative TB/HIV activities. J Acquir Immune Defic Syndr 2012; 60:S136-S144.
36. Lawn SD, Campbell L, Kaplan R, et al. Delays in starting antiretroviral therapy in patients with HIV-associated tuberculosis accessing nonintegrated clinical services in a South African township. BMC Infect Dis 2011; 11:258.
37. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359:2233-2244.
38. Marais BJ, Rabie H, Cotton MF. TB and HIV in children-advances in prevention and management. Paediatr Respir Rev 2011; 12:39-45.